The smoothened (SMO) receptor, a signal transducer in the hedgehog/patched protein signaling pathway, is responsible for the maintenance of normal embryonic development and is implicated in carcinogenesis. It is classified as a class frizzled (class F) G-protein-coupled receptor (GPCR). Smoothened is activated in a number of human tumors and can function as an oncogene in basal-cell carcinomas. Use this new tool to study the therapeutic potential of Hedgehog (Hh) pathway inhibitors and Smoothened (SMO) antagonists as emerging anticancer therapies.
Anti-Smoothened (SMO)-SAP eliminates cells expressing the smoothened (SMO) receptor.
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.